69,029 Shares in IQVIA Holdings Inc. $IQV Purchased by Thornburg Investment Management Inc.

Key Points

• Thornburg Investment Management purchased 69,029 IQVIA shares worth approximately $13.3 million, while institutional investors collectively own 89.62% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $241.88; RBC and BMO recently raised their targets to $247 and $270, respectively.
• IQVIA exceeded quarterly expectations with adjusted EPS of $3.15 and revenue of $4.37 billion, up 8.7% year over year. The company also authorized a $2 billion share-repurchase program, covering up to 6.8% of its outstanding stock.

Thornburg Investment Management Inc. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 69,029 shares of the medical research company's stock, valued at approximately $13,338,000.

Several other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Boston Partners bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $676,698,000. Norges Bank purchased a new position in IQVIA in the fourth quarter valued at approximately $497,445,000. Victory Capital Management Inc. grew its holdings in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in IQVIA during the second quarter valued at $240,911,000. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. Royal Bank Of Canada increased their price target on IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. BMO Capital Markets boosted their price objective on IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. HSBC reaffirmed a "buy" rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $241.88.

Insiders Place Their Bets

In related news, insider W Richard Staub sold 5,500 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company's stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company's stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. Company insiders own 1.70% of the company's stock.

IQVIA Trading Down 0.7%

IQVIA stock opened at $260.48 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $265.25. The stock has a market cap of $42.88 billion, a P/E ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. The firm's fifty day moving average price is $222.14 and its 200-day moving average price is $189.62.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its stock is undervalued.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source